Lv21
170 积分 2024-09-02 加入
YAP regulates HER3 signaling-driven adaptive resistance to RET inhibitors in RET-aberrant cancer
1小时前
已完结
MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer
1小时前
已完结
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
16天前
已完结
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
16天前
已完结
A comprehensive analysis of deubiquitinase USP20 on prognosis and immunity in pan‐cancer
4个月前
已完结
Selpercatinib in RET Fusion–Positive Non–Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial
6个月前
已关闭
An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC)
6个月前
已完结
Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience
9个月前
已完结
Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis
11个月前
已完结
Chatbots in science: What can ChatGPT do for you?
11个月前
已完结
皖公网安备34019202002308
